Potassium Chloride 15% Injection: IV Dilution and Dose
Potassium chloride 15% injectable guidance for severe hypokalaemia, with dilution-only IV infusion dosing and monitoring precautions.
Also searched as
Source reviewed
February 2024
Guide category
Injectable drugs
Safety boundary
Prescription medicine information for clinician-guided use.
Kenza Health Hub presents this medicine page as structured health education. Check dose, route, interactions, pregnancy or breast-feeding considerations, and local protocol with a qualified clinician or pharmacist. Read our medical editorial policy.
Quick clinical summary
| Item | Summary |
|---|---|
| Drug | Potassium chloride 15%, also written KCl 15% |
| Common form | 150 mg/ml, 10 ml ampoule |
| Electrolyte content | 20 mmol potassium per 10 ml ampoule |
| Route | Slow IV infusion only after dilution |
| Direct injection | Never direct undiluted IV, IM, or SC injection |
| Major concern | Fatal cardiac rhythm disturbance if given too rapidly or in excess |
| Monitoring | Infusion rate, infusion site, electrolytes, and ECG for higher-risk use |
Clinical context from Kenza
The sections below add practical explanation around the source-derived monograph. They are educational context and do not replace local protocols or clinician review.
Potassium chloride 15% explained
The 15% label describes concentration. In this guide, a 10 ml ampoule contains 1.5 g potassium chloride and provides 20 mmol of potassium, so dose calculations should follow mmol requirements rather than the percentage label alone.
Why dilution is non-negotiable
Potassium chloride concentrate can be dangerous if delivered as a bolus or in the wrong concentration. Dilution, pump control where available, and clear labelling help prevent accidental rapid administration.
What clinicians monitor during IV potassium
- The infusion site for pain, redness, inflammation, phlebitis, or extravasation.
- Electrolytes when possible, especially if repeat infusions are being considered.
- ECG monitoring for higher doses, higher infusion rates, renal impairment, or cardiac risk.
Indications
Treatment of severe hypokalaemia, including arrhythmia, marked muscular weakness, and/or serum potassium level 2.5 mmol/litre or less.
Forms and strengths, route of administration
This drug should only be used by well-trained personnel in well-equipped hospitals.
Ampoule containing 15% potassium chloride hypertonic solution (150 mg/ml, 10 ml = 2 mmol/ml), i.e. 1.5 g of potassium chloride per 10 ml ampoule.
Ionic composition: potassium 20 mmol per 10 ml ampoule (20 mEq) and chloride 20 mmol per 10 ml ampoule (20 mEq).
Check concentration before use: potassium chloride also comes in ampoules containing 7.5%, 10%, 11.2%, and 20% solutions.
Dosage and duration
Dosage depends on the severity of hypokalaemia and the patient's underlying condition.
Potassium chloride must always be administered by slow IV infusion, diluted in 0.9% sodium chloride.
The potassium concentration in the infusion fluid should not exceed 40 mmol/litre.
Mix thoroughly the potassium and 0.9% sodium chloride solution by inverting the infusion bottle or bag at least 5 times.
Never use by direct undiluted IV, IM, or SC injection.
- Child over one month: 0.2 mmol/kg/hour for 3 hours. Each mmol of potassium is diluted in 25 ml of 0.9% sodium chloride.
- Do not exceed 10 mmol/hour. The infusion may be repeated if severe symptoms persist or if the serum potassium level remains under 3 mmol/litre.
- Adult: 40 mmol (2 ampoules of 10 ml of 15% KCl) in one litre of 0.9% sodium chloride, administered over 4 hours.
| Weight | Dilution and administration |
|---|---|
| 10 kg | 0.2 mmol x 10 kg = 2 mmol/hour x 3 hours = 6 mmol. Dilute 6 mmol (3 ml of 15% KCl solution) in 150 ml of 0.9% sodium chloride and administer over 3 hours. |
| 15 kg | 0.2 mmol x 15 kg = 3 mmol/hour x 3 hours = 9 mmol. Dilute 9 mmol (4.5 ml of 15% KCl solution) in 225 ml of 0.9% sodium chloride and administer over 3 hours. |
Contra-indications, adverse effects, precautions
- Administer with caution to older adults.
- Administer with caution and reduce the dose in patients with renal impairment because of increased risk of hyperkalaemia.
- May cause pain at infusion site, venous irritation, and phlebitis. Use a large peripheral vein to reduce these risks.
- Too rapid administration or overdose may cause hyperkalaemia and potentially fatal cardiac conduction and rhythm disorders.
- Extravasation may cause necrosis.
- Monitor infusion rate, using an infusion pump or syringe pump if possible to prevent unintentional bolus.
- Monitor infusion site for redness and inflammation.
- Monitor electrolytes if possible to determine the need for further infusions and avoid hyperkalaemia.
- Higher dose or infusion rate requires continuous electrocardiogram monitoring.
- Potassium chloride is also used to prevent hypokalaemia in patients unable to meet daily requirements by oral route.
- Daily potassium requirements are 2 to 3 mmol/kg daily in children and 1 to 2 mmol/kg daily in adults.
- A 7.5% potassium solution contains 1 mmol/ml; a 10% solution contains 1.34 mmol/ml; an 11.2% solution contains 1.5 mmol/ml; and a 20% solution contains 2.68 mmol/ml.
Frequently Asked Questions
Potassium chloride 15% = KCl 15% injectable dose and administration questions
What is potassium chloride 15% injection used for?
This guide lists potassium chloride 15% injectable for severe hypokalaemia, including arrhythmia, marked muscular weakness, or serum potassium of 2.5 mmol/litre or less.
Can potassium chloride 15% be given by direct injection?
No. The guide says potassium chloride must always be given by slow IV infusion after dilution in 0.9% sodium chloride, and never by direct undiluted IV, IM, or SC injection.
What is the maximum potassium concentration in the infusion fluid?
The guide says the potassium concentration in the infusion fluid should not exceed 40 mmol/litre.
What monitoring is needed during potassium chloride IV infusion?
The page notes monitoring the infusion rate, infusion site, and electrolytes where possible. Higher doses or infusion rates require continuous ECG monitoring.
Source
MSF Essential drugs practical guidelines (January 2026)
This page combines source-derived medicine reference sections with Kenza editorial context, while leaving out the Storage and Remarks sections from the source batch.
Additional medical references
Rate this guide
Be the first to rate this guide.